Literature DB >> 10216148

Modeling the hepatitis C virus epidemic in France.

S Deuffic1, L Buffat, T Poynard, A J Valleron.   

Abstract

A backcalculation approach allows a reconstruction of the history of hepatitis C virus (HCV) infection in France and predictions of mortality from hepatocellular carcinoma (HCC) related to the virus. The model uses information from the literature about the natural history of the disease, epidemiological data about infected subjects in three French cohorts, and mortality data from national statistics. It seeks to determine the annual transition probabilities from chronic hepatitis to cirrhosis and the HCV incidence per year in the past. These unknowns are found by fitting the observed deaths from HCC that are attributable to HCV. Optimal values for these unknowns then allow to project the number of HCC deaths attributable to HCV for each year through 2025 (for patients infected before 1996). The model traces the HCV epidemic in France back to around the 1940s. It predicts that HCC mortality related to HCV will continue to increase through 2020 in the absence of treatment, with a 150% increase in the yearly incidence among men and 200% among women. The model also confirms that progression to cirrhosis depends strongly on sex and age. At any age, the annual probability of progression is 10 times greater for men than for women. Moreover, for men aged between 61 and 70 years, this probability is 300 times greater than that for men aged between 21 and 40 years.

Entities:  

Mesh:

Year:  1999        PMID: 10216148     DOI: 10.1002/hep.510290528

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  36 in total

1.  Estimating future hepatitis C morbidity, mortality, and costs in the United States.

Authors:  J B Wong; G M McQuillan; J G McHutchison; T Poynard
Journal:  Am J Public Health       Date:  2000-10       Impact factor: 9.308

Review 2.  Treatment of hepatitis C. The 2002 French consensus.

Authors:  D Dhumeaux; P Marcellin; E Lerebours
Journal:  Gut       Date:  2003-12       Impact factor: 23.059

Review 3.  Hepatitis C: cost of illness and considerations for the economic evaluation of antiviral therapies.

Authors:  John B Wong
Journal:  Pharmacoeconomics       Date:  2006       Impact factor: 4.981

4.  Antiviral Therapy in Elderly Patients With Hepatitis C Virus Infection.

Authors:  Justin Rheem; Vinay Sundaram; Sammy Saab
Journal:  Gastroenterol Hepatol (N Y)       Date:  2015-05

Review 5.  Global control of hepatitis C: where challenge meets opportunity.

Authors:  David L Thomas
Journal:  Nat Med       Date:  2013-07       Impact factor: 53.440

6.  Hepatitis C virus-related complications are increasing in women veterans: A national cohort study.

Authors:  J R Kramer; H B El-Serag; T J Taylor; D L White; S M Asch; S M Frayne; Y Cao; D L Smith; F Kanwal
Journal:  J Viral Hepat       Date:  2017-08-16       Impact factor: 3.728

7.  Expression of lysosome-associated protein transmembrane 4B-35 in cancer and its correlation with the differentiation status of hepatocellular carcinoma.

Authors:  Cong Peng; Rou-Li Zhou; Gen-Ze Shao; Jing-An Rui; Shao-Bin Wang; Ming Lin; Sha Zhang; Zi-Feng Gao
Journal:  World J Gastroenterol       Date:  2005-05-14       Impact factor: 5.742

Review 8.  Alcohol has no effect on hepatitis C virus replication: a meta-analysis.

Authors:  B S Anand; J Thornby
Journal:  Gut       Date:  2005-10       Impact factor: 23.059

9.  Two successive hepatitis C virus infections in an intravenous drug user.

Authors:  B Proust; F Dubois; Y Bacq; S Le Pogam; S Rogez; R Levillain; A Goudeau
Journal:  J Clin Microbiol       Date:  2000-08       Impact factor: 5.948

10.  Hepatitis C virus (HCV) genotypes in the Caribbean island of Martinique: evidence for a large radiation of HCV-2 and for a recent introduction from Europe of HCV-4.

Authors:  Jenny Martial; Yoann Morice; Sylvie Abel; André Cabié; Christelle Rat; Frédéric Lombard; André Edouard; Serge Pierre-Louis; Philippe Garsaud; Odile Béra; Roger Chout; Emmanuel Gordien; Paul Deny; Raymond Césaire
Journal:  J Clin Microbiol       Date:  2004-02       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.